Italia markets open in 1 hour 59 minutes
Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.643,07 +469,92 (+1,20%) EUR/USD
1,0714 -0,0002 (-0,02%) Bitcoin EUR
57.617,46 +348,34 (+0,61%) CMC Crypto 200
1.280,80 +31,68 (+2,54%)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (08HH.SG)
Stuttgart - Stuttgart Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
Alla chiusura: 08:10AM CEST
| Chiusura precedente | 1,5060 |
| Aperto | 1,5470 |
| Denaro | 0,0000 x 700000 |
| Domanda | 0,0000 x 1100000 |
| Min-Max giorno | 1,5470 - 1,5470 |
| Intervallo di 52 settimane | 1,3390 - 2,4610 |
| Volume | |
| Media Volume | 103 |
| Capitalizzazione | 7,193B |
| Beta (mensile su 5 anni) | 0,62 |
| Rapporto PE (ttm) | 15,47 |
| EPS (ttm) | 0,1000 |
| Prossima data utili | 27 ago 2024 - 02 set 2024 |
| Rendimento e dividendo (futuro) | 0,05 (3,59%) |
| Data ex dividendo | 31 lug 2023 |
| Stima target 1A | N/D |
GlobeNewswireArdelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun PharmaWALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that a New Drug Application (NDA) for tenapanor has been accepted for review by China’s Center for Drug Evaluation of the National Medical
© 2024 Yahoo. Tutti i diritti riservati.